Watchtower/Law library/Money Laundering, Terrorist.../33 Obligation to apply enhanced...
As last captured

Money Laundering, Terrorist Financing and Transfer of Funds... · CHAPTER 2 Enhanced customer due diligence

33 Obligation to apply enhanced customer due diligence

reg. 33 · in force: yes

Captured statutory text (L5)

33 Obligation to apply enhanced customer due diligence

(1)A relevant person must apply enhanced customer due diligence measures and enhanced ongoing monitoring, in addition to the customer due diligence measures required under regulation 28 and, if applicable, regulation 29, to manage and mitigate the risks arising—
(a)in any case identified as one where there is a high risk of money laundering or terrorist financing—
(i)by the relevant person under regulation 18(1), or
(ii)in information made available to the relevant person under regulations 17(9) and 47;
(b)in any business relationship ... with a person established in a FATF call for action country or in relation to any relevant transaction where either of the parties to the transaction is established in a FATF call for action country;
(c)in relation to correspondent relationships with a credit institution or a financial institution (in accordance with regulation 34);
(d)if a relevant person has determined that a customer or potential customer is a PEP, or a family member or known close associate of a PEP (in accordance with regulation 35);
(e)in any case where the relevant person discovers that a customer has provided false or stolen identification documentation or information and the relevant person proposes to continue to deal with that customer;
(f)in any case where—
(i)a transaction is unusually complex or unusually large in each case given the nature of the transaction,
(ii)there is an unusual pattern of transactions, or
(iii)the transaction or transactions have no apparent economic or legal purpose, and
(g)in any other case which by its nature can present a higher risk of money laundering or terrorist financing.
(2)Paragraph (1)(b) does not apply when the customer is a branch or majority owned subsidiary undertaking of an entity which is established in a third country if all the following conditions are satisfied—
(a)the entity is—
(i)subject to requirements in national legislation having an equivalent effect to those laid down in the fourth money laundering directive on an obliged entity (within the meaning of that directive); and
(ii)supervised for compliance with those requirements in a manner equivalent to section 2 of Chapter VI of the fourth money laundering directive;
(b)the branch or subsidiary complies fully with procedures and policies established for the group under requirements equivalent to those laid down in Article 45 of the fourth money laundering directive; and
(c)the relevant person, applying a risk-based approach, does not consider that it is necessary to apply enhanced customer due diligence measures.
(3)For the purposes of paragraph (1)(b)—
(a)a “FATF call for action country” means a country named on the list of High-Risk Jurisdictions subject to a Call for Action published by the Financial Action Task Force as such list has effect from time to time;
(b)a “relevant transaction” means a transaction in relation to which the relevant person is required to apply customer due diligence measures under regulation 27;
(c)being “established in” a country means—
(i)in the case of a legal person, being incorporated in or having its principal place of business in that country, or, in the case of a financial institution or a credit institution, having its principal regulatory authority in that country; and
(ii)in the case of an individual, being resident in that country, but not merely having been born in that country.
(3A)The enhanced due diligence measures taken by a relevant person for the purpose of paragraph (1)(b) must include—
(a)obtaining additional information on the customer and on the customer’s beneficial owner;
(b)obtaining additional information on the intended nature of the business relationship;
(c)obtaining information on the source of funds and source of wealth of the customer and of the customer’s beneficial owner;
(d)obtaining information on the reasons for the transactions;
(e)obtaining the approval of senior management for establishing or continuing the business relationship;
(f)conducting enhanced monitoring of the business relationship by increasing the number and timing of controls applied, and selecting patterns of transactions that need further examination.
(4)The enhanced customer due diligence measures taken by a relevant person for the purpose of paragraph (1)(f) must include—
(a)as far as reasonably possible, examining the background and purpose of the transaction, and
(b)increasing the degree and nature of monitoring of the business relationship in which the transaction is made to determine whether that transaction or that relationship appear to be suspicious.
(4A)Where a relevant person provides a life insurance policy, the relevant person must consider the nature and identity of the beneficiary of the policy when assessing whether there is a high risk of money laundering or terrorist financing, and the extent of the measures which should be taken to manage and mitigate that risk.
(4B)Where the beneficiary of a life insurance policy provided by a relevant person—
(a)is a legal person or a legal arrangement, and
(b)presents a high risk of money laundering or terrorist financing,
the relevant person must take reasonable measures to identify and verify the identity of the beneficial owner of that beneficiary before any payment is made under the policy.
(5)Depending on the requirements of the case, the enhanced customer due diligence measures required under paragraph (1) may also include, among other things—
(a)seeking additional independent, reliable sources to verify information provided or made available to the relevant person;
(b)taking additional measures to understand better the background, ownership and financial situation of the customer, and other parties to the transaction;
(c)taking further steps to be satisfied that the transaction is consistent with the purpose and intended nature of the business relationship;
(d)increasing the monitoring of the business relationship, including greater scrutiny of transactions.
(6)When assessing whether there is a high risk of money laundering or terrorist financing in a particular situation, and the extent of the measures which should be taken to manage and mitigate that risk, relevant persons must take account of risk factors including, among other things—
(a)customer risk factors, including whether—
(i)the business relationship is conducted in unusual circumstances;
(ii)the customer is resident in a geographical area of high risk (see sub-paragraph (c));
(iii)the customer is a legal person or legal arrangement that is a vehicle for holding personal assets;
(iv)the customer is a company that has nominee shareholders or shares in bearer form;
(v)the customer is a business that is cash intensive;
(vi)the corporate structure of the customer is unusual or excessively complex given the nature of the company's business;
(vii)the customer is the beneficiary of a life insurance policy;
(viii)the customer is a third country national who is applying for residence rights in or citizenship of a state in exchange for transfers of capital, purchase of a property, government bonds or investment in corporate entities in that state;
(b)product, service, transaction or delivery channel risk factors, including whether—
(i)the product involves private banking;
(ii)the product or transaction is one which might favour anonymity;
(iii)the situation involves non-face-to-face business relationships or transactions, without certain safeguards, such as an electronic identification process which meets the conditions set out in regulation 28(19);
(iv)payments will be received from unknown or unassociated third parties;
(v)new products and new business practices are involved, including new delivery mechanisms, and the use of new or developing technologies for both new and pre-existing products;
(vi)the service involves the provision of nominee directors, nominee shareholders or shadow directors, or the formation of companies in a third country;
(vii)there is a transaction related to oil, arms, precious metals, tobacco products, cultural artefacts, ivory or other items related to protected species, or other items of archaeological, historical, cultural or religious significance or of rare scientific value;
(c)geographical risk factors, including—
(i)countries identified by credible sources, such as mutual evaluations, detailed assessment reports or published follow-up reports, as not having effective systems to counter money laundering or terrorist financing;
(ii)countries identified by credible sources as having significant levels of corruption or other criminal activity, such as terrorism (within the meaning of section 1 of the Terrorism Act 2000 ), money laundering, and the production and supply of illicit drugs;
(iii)countries subject to sanctions, embargos or similar measures issued by, for example, the European Union or the United Nations;
(iv)countries providing funding or support for terrorism;
(v)countries that have organisations operating within their territory which have been designated—
(aa)by the government of the United Kingdom as proscribed organisations under Schedule 2 to the Terrorism Act 2000 , or
(bb)by other countries, international organisations or the European Union as terrorist organisations;
(vi)countries identified by credible sources, such as evaluations, detailed assessment reports or published follow-up reports published by the Financial Action Task Force, the International Monetary Fund, the World Bank, the Organisation for Economic Co-operation and Development or other international bodies or non-governmental organisations as not implementing requirements to counter money laundering and terrorist financing that are consistent with the recommendations published by the Financial Action Task Force in February 2012 and updated in June 2019.
(7)In making the assessment referred to in paragraph (6), relevant persons must bear in mind that the presence of one or more risk factors may not always indicate that there is a high risk of money laundering or terrorist financing in a particular situation.
(8). . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Full captured verbatim text
(1) A relevant person must apply enhanced customer due diligence measures and enhanced ongoing monitoring, in addition to the customer due diligence measures required under regulation 28 and, if applicable, regulation 29, to manage and mitigate the risks arising—

(a) in any case identified as one where there is a high risk of money laundering or terrorist financing—

(i) by the relevant person under regulation 18(1), or

(ii) in information made available to the relevant person under regulations 17(9) and 47;

(b) in any business relationship ... with a person established in a FATF call for action country or in relation to any relevant transaction where either of the parties to the transaction is established in a FATF call for action country;

(c) in relation to correspondent relationships with a credit institution or a financial institution (in accordance with regulation 34);

(d) if a relevant person has determined that a customer or potential customer is a PEP, or a family member or known close associate of a PEP (in accordance with regulation 35);

(e) in any case where the relevant person discovers that a customer has provided false or stolen identification documentation or information and the relevant person proposes to continue to deal with that customer;

(f) in any case where—

(i) a transaction is unusually complex or unusually large in each case given the nature of the transaction,

(ii) there is an unusual pattern of transactions, or

(iii) the transaction or transactions have no apparent economic or legal purpose, and

(g) in any other case which by its nature can present a higher risk of money laundering or terrorist financing.

(2) Paragraph (1)(b) does not apply when the customer is a branch or majority owned subsidiary undertaking of an entity which is established in a third country if all the following conditions are satisfied—

(a) the entity is—

(i) subject to requirements in national legislation having an equivalent effect to those laid down in the fourth money laundering directive on an obliged entity (within the meaning of that directive); and

(ii) supervised for compliance with those requirements in a manner equivalent to section 2 of Chapter VI of the fourth money laundering directive;

(b) the branch or subsidiary complies fully with procedures and policies established for the group under requirements equivalent to those laid down in Article 45 of the fourth money laundering directive; and

(c) the relevant person, applying a risk-based approach, does not consider that it is necessary to apply enhanced customer due diligence measures.

(3) For the purposes of paragraph (1)(b)—

(a) a “FATF call for action country” means a country named on the list of High-Risk Jurisdictions subject to a Call for Action published by the Financial Action Task Force as such list has effect from time to time;

(b) a “relevant transaction” means a transaction in relation to which the relevant person is required to apply customer due diligence measures under regulation 27;

(c) being “established in” a country means—

(i) in the case of a legal person, being incorporated in or having its principal place of business in that country, or, in the case of a financial institution or a credit institution, having its principal regulatory authority in that country; and

(ii) in the case of an individual, being resident in that country, but not merely having been born in that country.

(3A) The enhanced due diligence measures taken by a relevant person for the purpose of paragraph (1)(b) must include—

(a) obtaining additional information on the customer and on the customer’s beneficial owner;

(b) obtaining additional information on the intended nature of the business relationship;

(c) obtaining information on the source of funds and source of wealth of the customer and of the customer’s beneficial owner;

(d) obtaining information on the reasons for the transactions;

(e) obtaining the approval of senior management for establishing or continuing the business relationship;

(f) conducting enhanced monitoring of the business relationship by increasing the number and timing of controls applied, and selecting patterns of transactions that need further examination.

(4) The enhanced customer due diligence measures taken by a relevant person for the purpose of paragraph (1)(f) must include—

(a) as far as reasonably possible, examining the background and purpose of the transaction, and

(b) increasing the degree and nature of monitoring of the business relationship in which the transaction is made to determine whether that transaction or that relationship appear to be suspicious.

(4A) Where a relevant person provides a life insurance policy, the relevant person must consider the nature and identity of the beneficiary of the policy when assessing whether there is a high risk of money laundering or terrorist financing, and the extent of the measures which should be taken to manage and mitigate that risk.

(4B) Where the beneficiary of a life insurance policy provided by a relevant person—

(a) is a legal person or a legal arrangement, and

(b) presents a high risk of money laundering or terrorist financing,

the relevant person must take reasonable measures to identify and verify the identity of the beneficial owner of that beneficiary before any payment is made under the policy.

(5) Depending on the requirements of the case, the enhanced customer due diligence measures required under paragraph (1) may also include, among other things—

(a) seeking additional independent, reliable sources to verify information provided or made available to the relevant person;

(b) taking additional measures to understand better the background, ownership and financial situation of the customer, and other parties to the transaction;

(c) taking further steps to be satisfied that the transaction is consistent with the purpose and intended nature of the business relationship;

(d) increasing the monitoring of the business relationship, including greater scrutiny of transactions.

(6) When assessing whether there is a high risk of money laundering or terrorist financing in a particular situation, and the extent of the measures which should be taken to manage and mitigate that risk, relevant persons must take account of risk factors including, among other things—

(a) customer risk factors, including whether—

(i) the business relationship is conducted in unusual circumstances;

(ii) the customer is resident in a geographical area of high risk (see sub-paragraph (c));

(iii) the customer is a legal person or legal arrangement that is a vehicle for holding personal assets;

(iv) the customer is a company that has nominee shareholders or shares in bearer form;

(v) the customer is a business that is cash intensive;

(vi) the corporate structure of the customer is unusual or excessively complex given the nature of the company's business;

(vii) the customer is the beneficiary of a life insurance policy;

(viii) the customer is a third country national who is applying for residence rights in or citizenship of a state in exchange for transfers of capital, purchase of a property, government bonds or investment in corporate entities in that state;

(b) product, service, transaction or delivery channel risk factors, including whether—

(i) the product involves private banking;

(ii) the product or transaction is one which might favour anonymity;

(iii) the situation involves non-face-to-face business relationships or transactions, without certain safeguards, such as an electronic identification process which meets the conditions set out in regulation 28(19);

(iv) payments will be received from unknown or unassociated third parties;

(v) new products and new business practices are involved, including new delivery mechanisms, and the use of new or developing technologies for both new and pre-existing products;

(vi) the service involves the provision of nominee directors, nominee shareholders or shadow directors, or the formation of companies in a third country;

(vii) there is a transaction related to oil, arms, precious metals, tobacco products, cultural artefacts, ivory or other items related to protected species, or other items of archaeological, historical, cultural or religious significance or of rare scientific value;

(c) geographical risk factors, including—

(i) countries identified by credible sources, such as mutual evaluations, detailed assessment reports or published follow-up reports, as not having effective systems to counter money laundering or terrorist financing;

(ii) countries identified by credible sources as having significant levels of corruption or other criminal activity, such as terrorism (within the meaning of section 1 of the Terrorism Act 2000 ), money laundering, and the production and supply of illicit drugs;

(iii) countries subject to sanctions, embargos or similar measures issued by, for example, the European Union or the United Nations;

(iv) countries providing funding or support for terrorism;

(v) countries that have organisations operating within their territory which have been designated—

(aa) by the government of the United Kingdom as proscribed organisations under Schedule 2 to the Terrorism Act 2000 , or

(bb) by other countries, international organisations or the European Union as terrorist organisations;

(vi) countries identified by credible sources, such as evaluations, detailed assessment reports or published follow-up reports published by the Financial Action Task Force, the International Monetary Fund, the World Bank, the Organisation for Economic Co-operation and Development or other international bodies or non-governmental organisations as not implementing requirements to counter money laundering and terrorist financing that are consistent with the recommendations published by the Financial Action Task Force in February 2012 and updated in June 2019.

(7) In making the assessment referred to in paragraph (6), relevant persons must bear in mind that the presence of one or more risk factors may not always indicate that there is a high risk of money laundering or terrorist financing in a particular situation.

(8) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .

What this provision means

Model summary, checked against the text on the left.

Relevance to Signicat: 3/3 · detailed summary (L4) Status: ok · Stored artifact; current recipe verification unavailable

Relevant persons must apply enhanced customer due diligence and enhanced ongoing monitoring in high-risk scenarios and FATF call for action cases.

(1) A relevant person must apply enhanced customer due diligence measures and enhanced ongoing monitoring, in addition to the customer due diligence measures required under regulation 28 and, if applicable, regulation 29, to manage and mitigate the risks arising—
(2) Paragraph (1)(b) does not apply when the customer is a branch or majority owned subsidiary undertaking of an entity which is established in a third country if all the following conditions are satisfied—
(3A) The enhanced due diligence measures taken by a relevant person for the purpose of paragraph (1)(b) must include—
Under (1), a relevant person must apply enhanced customer due diligence and ongoing monitoring where high risk is identified under (1)(a), in relationships or transactions involving a FATF call for action country under (1)(b), correspondent relationships under (1)(c), PEP situations under (1)(d), where false or stolen identification documentation or information was provided under (1)(e), complex or unusual transactions under (1)(f), or any higher risk case under (1)(g). For FATF countries, (3A) mandates additional information on customer and beneficial owner, intended nature, source of wealth or funds, transaction reasons, senior management approval, and enhanced transaction controls. Under (4B), beneficial owners of high-risk legal entity beneficiaries under life insurance must be verified before payment.
identity_proofing.data_verificationidentity_proofing.documentmonitoring.ongoing_kycmonitoring.transactions_amlscreening.pep_sanctions_adverse_media

Refers to

other law external_cite · s. 1

cross-reference internal_cite · reg. 17

cross-reference internal_cite · reg. 18

cross-reference internal_cite · reg. 27

cross-reference internal_cite · reg. 28

cross-reference internal_cite · reg. 29

cross-reference internal_cite · reg. 34

cross-reference internal_cite · reg. 35

cross-reference internal_cite · reg. 47

Referred to by

cross-reference internal_cite · reg. 19

cross-reference internal_cite · reg. 3

cross-reference internal_cite · reg. 30ZA

cross-reference internal_cite · reg. 34

cross-reference internal_cite · reg. 35

cross-reference internal_cite · reg. 37

cross-reference internal_cite · reg. 38

cross-reference internal_cite · reg. 39

cross-reference internal_cite · reg. 40

cross-reference internal_cite · Sch. 6 para. 7

cross-reference internal_cite · Sch. 7 para. 12

Part summaries

0 of 0 parts have a verified summary.

L1 unavailable for current verification: the overall summary needs every part verified. Provisions and the verified summaries remain readable.

Verification findings (348)

synthesis coverage: missing/unverified L2 part-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-4

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-5

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-6

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-7

synthesis coverage: missing/unverified L2 part-2-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-8

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-9

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-10

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-11

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-12

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-13

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-14

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-14A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-15

synthesis coverage: missing/unverified L2 part-2-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-16

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-16A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-17

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-18

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-18A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-19

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-19A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-20

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-21

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-22

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-23

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-24

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-25

synthesis coverage: missing/unverified L2 part-2-chapter-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-26

synthesis coverage: missing/unverified L2 part-3-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-27

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-28

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-29

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-30

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-30ZA

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-30A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-31

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-32

synthesis coverage: missing/unverified L2 part-3-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-33

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-34

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-35

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-36

synthesis coverage: missing/unverified L2 part-3-chapter-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-37

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-38

synthesis coverage: missing/unverified L2 part-4

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-39

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-40

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-41

synthesis coverage: missing/unverified L2 part-5

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-42

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-43

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-44

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45ZA

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45ZB

synthesis coverage: missing/unverified L2 part-5A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45B

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45C

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45D

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45E

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45F

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45G

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-45H

synthesis coverage: missing/unverified L2 part-6-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-46

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-46A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-47

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-48

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-49

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-50

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-51

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-52

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-52A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-52B

synthesis coverage: missing/unverified L2 part-6-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-53

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-54

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-55

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-56

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-56A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-56B

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-57

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-58

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-58A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-59

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-60

synthesis coverage: missing/unverified L2 part-6-chapter-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-60A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-60B

synthesis coverage: missing/unverified L2 part-7

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-61

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-62

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-63

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64

synthesis coverage: missing/unverified L2 part-7A-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64B

synthesis coverage: missing/unverified L2 part-7A-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64C

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64D

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64E

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64F

synthesis coverage: missing/unverified L2 part-7A-chapter-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64G

synthesis coverage: missing/unverified L2 part-7A-chapter-4

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-64H

synthesis coverage: missing/unverified L2 part-8

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-65

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-66

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-67

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-68

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-69

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-70

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-71

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-72

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-73

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-74

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-74A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-74B

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-74C

synthesis coverage: missing/unverified L2 part-9-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-75

synthesis coverage: missing/unverified L2 part-9-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-76

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-77

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-78

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-79

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-80

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-81

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-82

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-83

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-84

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-85

synthesis coverage: missing/unverified L2 part-9-chapter-3

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-86

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-87

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-88

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-89

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-90

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-91

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-92

synthesis coverage: missing/unverified L2 part-10-chapter-1

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-93

synthesis coverage: missing/unverified L2 part-10-chapter-2

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-94

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-95

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-96

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-97

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-98

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-99

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-100

synthesis coverage: missing/unverified L2 part-11

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-101

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-102

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-103

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-104

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-104A

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-105

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-106

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-107

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-108

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-109

synthesis coverage: missing evaluation uk:uksi/2017/692#regulation-110

synthesis coverage: missing/unverified L2 schedule-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-19

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-20

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-21

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-22

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-23

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-24

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-25

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-26

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-27

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-27A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-28

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-29

synthesis coverage: missing/unverified L2 schedule-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-30

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-31

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-32

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-33

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-34

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3-paragraph-35

synthesis coverage: missing/unverified L2 schedule-3AZA

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3AZA-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3AZA-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3AZA-paragraph-3

synthesis coverage: missing/unverified L2 schedule-3A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-1A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-6A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-8A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-9A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-9B

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-19

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-20

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-21

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-22

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-23

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-23A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-3A-paragraph-24

synthesis coverage: missing/unverified L2 schedule-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-12A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-15A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-4-paragraph-19

synthesis coverage: missing/unverified L2 schedule-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-5-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-5-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-5-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-5-paragraph-4

synthesis coverage: missing/unverified L2 schedule-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-9A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-11A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6-paragraph-13

synthesis coverage: missing/unverified L2 schedule-6A

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-11

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6A-paragraph-16

synthesis coverage: missing/unverified L2 schedule-6B

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6B-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6B-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6B-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6B-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-6B-paragraph-5

synthesis coverage: missing/unverified L2 schedule-7-part-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-1

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-3

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-4

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-5

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-6

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-7

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-8

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-9

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-10

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-11

synthesis coverage: missing/unverified L2 schedule-7-part-2

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-12

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-13

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-14

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-15

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-16

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-17

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-18

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-19

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-20

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-21

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-22

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-23

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-24

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-25

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-26

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-27

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-28

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-29

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-30

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-31

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-32

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-33

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-34

synthesis coverage: missing evaluation uk:uksi/2017/692#schedule-7-paragraph-35

Instrument tier unavailable

Change history as published

Reg. 22 omitted (31.12.2020) by virtue of The Money Laundering and Transfer of Funds (Information) (Amendment) (EU Exit) Regulations 2019 (S.I. 2019/253), regs. 1(2), 5(4) (with savings in S.I. 2019/680, reg. 11); 2020 c. 1, Sch. 5 para. 1(1)

Pt. 5A omitted (1.9.2022) by virtue of The Money Laundering and Terrorist Financing (Amendment) (No. 2) Regulations 2022 (S.I. 2022/860), regs. 1(5), 10 · repeated 8×

Sch. 7 para. 27 revoked (24.2.2025) by The Procurement Act 2023 (Consequential and Other Amendments) Regulations 2025 (S.I. 2025/163), reg. 1(2), Sch. Pt. 2

Pending effects amendments not yet applied to this text

reg. 3(1) words inserted by The Money Laundering and Transfer of Funds (Information) (Amendment) (EU Exit) Regulations 2019 reg. 3(b) · Effective date unknown · reg. 3

reg. 34A inserted by The Money Laundering and Terrorist Financing (Amendment) Regulations 2026 reg. 20 · Effective date unknown

Sch. 6 para. 7(ga) inserted by The Money Laundering and Terrorist Financing (Amendment) Regulations 2026 reg. 36(b) · Effective date unknown · Sch. 6 para. 7

Provenance

Every claim the system makes about this text is traceable to these identifiers.

Instrument
uk:uksi/2017/692
Part
CHAPTER 2 Enhanced customer due diligence
Version
c5a0271554697d8359bede8a…
Content hash
sha256 5a52158b134a4af2ec5af652…
Source
legislation.gov.uk/uksi/2017/692